title: Immunotherapeutic activity of a recombinant combined gB-gD-gE vaccine against recurrent HSV-2 infections in a guinea pig model.
abstract: The guinea pig model of recurrent genital herpes simplex virus type 2 (HSV-2) infection was used to test the immunotherapeutic activity of a glycoprotein subunit vaccine. Vaccine formulation consisted of three recombinant herpes simplex virus (HSV) glycoproteins, namely gB1s, gD2t and gE1t, plus aluminium hydroxide [Al(OH)3)] adjuvant. One month after viral challenge, infected animals were therapeutically immunised by seven subcutaneous injections of a low dose of antigens with a weekly interval for the first five and a fortnightly interval for the last two administrations. Results showed that the treatment was highly effective in ameliorating the recidivist pathology of animals, suggesting that this kind of vaccine formulation and administration may be helpful for therapeutic intervention in humans affected by recurrent herpes infections.
authors.affiliation: Department of Experimental and Diagnostic Medicine, Section of Microbiology, University of Ferrara, Via Luigi Borsari 46, 44100 Ferrara, Italy. mns@unife.it
authors.forename: Roberto
authors.initials: R
authors.lastname: Manservigi
authors.forename: Anna
authors.initials: A
authors.lastname: Boero
authors.forename: Rafaela
authors.initials: R
authors.lastname: Argnani
authors.forename: Elisabetta
authors.initials: E
authors.lastname: Caselli
authors.forename: Silvia
authors.initials: S
authors.lastname: Zucchini
authors.forename: Vivì
authors.initials: V
authors.lastname: Miriagou
authors.forename: Penelope
authors.initials: P
authors.lastname: Mavromara
authors.forename: Michele
authors.initials: M
authors.lastname: Cilli
authors.forename: Maria Pia
authors.initials: MP
authors.lastname: Grossi
authors.forename: Pier Giorgio
authors.initials: PG
authors.lastname: Balboni
authors.forename: Enzo
authors.initials: E
authors.lastname: Cassai
mesh_terms: D000818:Animals; D004195:Disease Models, Animal; D005260:Female; D006023:Glycoproteins / Q000008:administration & dosage / Q000276:immunology; D006168:Guinea Pigs; D006561:Herpes Simplex / Q000276:immunology* / Q000517:prevention & control; D022301:Herpes Simplex Virus Vaccines / Q000008:administration & dosage / Q000276:immunology* / Q000627:therapeutic use*; D018258:Herpesvirus 2, Human / Q000276:immunology*; D022283:Herpesvirus Vaccines / Q000008:administration & dosage / Q000276:immunology / Q000627:therapeutic use; D022223:Vaccines, Subunit / Q000008:administration & dosage / Q000276:immunology / Q000627:therapeutic use; D014614:Vaccines, Synthetic / Q000008:administration & dosage / Q000276:immunology / Q000627:therapeutic use; D014759:Viral Envelope Proteins / Q000008:administration & dosage / Q000276:immunology* / Q000627:therapeutic use*
chemical_list: D006023:Glycoproteins; D022301:Herpes Simplex Virus Vaccines; D022283:Herpesvirus Vaccines; D022223:Vaccines, Subunit; D014614:Vaccines, Synthetic; D014759:Viral Envelope Proteins; C044525:glycoprotein B, herpes simplex virus type 2; C044768:glycoprotein E, herpes simplex virus type 1; C069093:herpes simplex virus-1 glycoprotein D vaccine